37 results on '"Han, B."'
Search Results
2. LBA57 Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study.
3. 148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis.
4. 948TiP Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components.
5. 31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma.
6. LBA4 The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial.
7. 1114P Comparative study of combined large cell neuroendocrine carcinoma and combined small cell carcinoma in resected high-grade neuroendocrine tumors of the lung.
8. 318OBoth low and high blood tumour mutational burden are favourable predictors with atezolizumab.
9. 172P A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer
10. 123P Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China.
11. 396OA multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer.
12. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
13. 94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
14. 37P PD-L1 on the endothelium of micrangium inside tumor: A novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 (TQ-B2450)?
15. 1788P Association between deep prostate-specific antigen decline and survival in patients with high-volume metastatic hormone-sensitive prostate cancer treated with rezvilutamide in the CHART trial.
16. 118O Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials.
17. LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen.
18. 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results.
19. Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.
20. 355P Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients.
21. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
22. 148P Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection.
23. 4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study.
24. Clinical relevance of TNM staging system according to breast cancer subtypes.
25. LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
26. 1791P Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202).
27. 1787P Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202).
28. 1997P The Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
29. 139P Rearranged during transfection (RET) partners identified by next-generation sequencing in Chinese patients with solid tumours.
30. Clinical relevance of TNM staging system according to breast cancer subtypes.
31. 35P Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population.
32. 170P Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade.
33. 149P Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma.
34. 143P Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study.
35. 142P Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival.
36. 117O Racial disparities in characteristics and prognosis in Asian versus white patients receiving atezolizumab: An ancillary analysis of POPLAR and OAK studies.
37. 510PCharacteristics and outcome of small cell lung cancer patients (SCLC) transformed from adenocarcinoma after tyrosine kinase inhibitor treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.